Jason McCarthy



Jason McCarthy's Group

My laboratory focuses upon the synthesis and application of nanomaterials in the imaging and therapy of disease. In particular, we are interested in the utility of these nanoagents in cardiovascular disease and its sequelae. Nanotechnology plays an increasing role in molecular diagnostics, in vivo imaging, and improved treatment of disease. The usefulness of nanoparticles is mainly derived from their small size, large surface area, and kinetics for in vivo drug delivery. The ability to functionalize the surface with targeting ligands, as well as imaging and therapeutic moieties also allows for the creation of multimodal, multifunctional nanoagents. The laboratory is part of the Chemical Biology Platform and the Nanotechnology Program at CSB, and collaborates with multidisciplinary groups across the Harvard Medical School community in order to focus upon clinically translatable strategies to fill unmet needs in disease detection and treatment.

Recent Publications (more...)

Stein-Merlob AF, Kessinger CW, Erdem SS, Zelada H, Hilderbrand SA, Lin CP, Tearney GJ, Jaff MR, Reed GL, Henke PK, McCarthy JR, Jaffer FA
Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.
Theranostics. 2015;5(12):1317-27 - PMID: 26516370 - PMCID: PMC4615735
Konishi M, Erdem SS, Weissleder R, Lichtman AH, McCarthy J, Libby P
Imaging Granzyme B Activity Assesses Immune-Mediated Myocarditis.
Circ Res. 2015;117(6):502-12 - PMID: 26199323 - PMCID: PMC4553143
Kessinger CW, Kim JW, Henke PK, Thompson B, McCarthy JR, Hara T, Sillesen M, Margey RJ, Libby P, Weissleder R, Lin CP, Jaffer FA
Statins Improve the Resolution of Established Murine Venous Thrombosis: Reductions in Thrombus Burden and Vein Wall Scarring.
PLoS ONE. 2015;10(2):e0116621 - PMID: 25680183 - PMCID: PMC4334538